Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microRNA-34a-5p

International Journal of Molecular Sciences

Volumn 19, Issue 2, 2018, Pages

  Jiang, Ze Qun ^a   Li, Mu Han ^a   Qin, Yue Mu ^a   Jiang, Hai Ying ^a   Zhang, Xu ^a   Wu, Mian Hua ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; CASPASE 9; KI 67 ANTIGEN; LET 7A 5P; LET 7B 5P; LET 7F 5P; LET 7I 5P; LUTEOLIN; MICRORNA 100 5P; MICRORNA 106A 5P; MICRORNA 17 5P; MICRORNA 181A 5P; MICRORNA 1983; MICRORNA 19B 3P; MICRORNA 208A 5P; MICRORNA 20A 5P; MICRORNA 222 3P; MICRORNA 34A; MICRORNA 34A 5P; MICRORNA 668 3P; MICRORNA 92A 3P; MICRORNA 93 5P; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MDM4 PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARCINOGENESIS; CELL COUNTING; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE CONTROL; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MALE; MICROARRAY ANALYSIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR WEIGHT; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LUTEOLIN; MALE; MICE; MICE, NUDE; MICROARRAY ANALYSIS; MICRORNAS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85041594131     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19020447     Document Type: Article

References (40)

1. Torre, L.A.; Sauer, A.M.G.; Chen, M.S.; Kagawa-Singer, M.; Jemal, A.; Siegel, R.L. Cancer statistics for Asian Americans, native hawaiians, and pacific islanders: Converging incidence in males and females. CA Cancer J. Clin. 2016, 66, 182–202. [CrossRef] [PubMed]
2. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584–594. [CrossRef]
3. Hussain, S. Nanomedicine for treatment of lung cancer. Adv. Exp. Med. Biol. 2016, 890, 137–147. [PubMed]
4. Yang, J.; Lin, J.; Liu, T.; Chen, T.; Pan, S.; Huang, W.; Li, S. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer 2014, 85, 110–115. [CrossRef] [PubMed]
5. Chen, Z.; Fillmore, C.M.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat. Rev. Cancer 2014, 14, 535–546. [CrossRef] [PubMed]
6. Araz, O.; Ucar, E.Y.; Meral, M.; Yalcin, A.; Acemoglu, H.; Dogan, H.; Karaman, A.; Aydin, Y.; Gorguner, M.; Akgun, M. Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival. Clin. Respir. J. 2015, 9, 297–304. [CrossRef] [PubMed]
7. Latimer, K.M.; Mott, T.F. Lung cancer: Diagnosis, treatment principles, and screening. Am. Fam. Physician 2015, 91, 250–256. [PubMed]
8. Laskin, J.J.; Sandler, A.B. State of the art in therapy for non-small cell lung cancer. Cancer Investig. 2005, 23, 427–442. [CrossRef]
9. Lin, Y.; Shi, R.; Wang, X.; Shen, H.M. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr. Cancer Drug Targets 2008, 8, 634–646. [CrossRef] [PubMed]
10. ′,5,7-tetrahydroxyflavone on A549 cells. Chin. J. Chin. Mater. Med. 2012, 37, 1259–1264.
11. Meng, G.; Chai, K.; Li, X.; Zhu, Y.; Huang, W. Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cells through the activation of MEK/ERK signaling pathway. Chem. Biol. Interact. 2016, 257, 26–34. [CrossRef] [PubMed]
12. Choi, H.J.; Choi, H.J.; Chung, T.W.; Ha, K.T. Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C-C motif) ligand 2 expression in tumor-associated macrophage. Biochem. Biophys. Res. Commun. 2016, 470, 101–106. [CrossRef] [PubMed]
13. Ji, W.; Sun, B.; Su, C. Targeting microRNAs in cancer gene therapy. Genes (Basel) 2017, 8, E21. [CrossRef] [PubMed]
14. Li, T.; Ding, Z.L.; Zheng, Y.L.; Wang, W. MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed. Pharmacother. 2017, 96, 153–164. [CrossRef] [PubMed]
15. Yin, Z.; Xu, M.; Li, P. miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. Gene 2017, 620, 46–53. [CrossRef] [PubMed]
16. Li, J.; Tang, Z.; Wang, H.; Wu, W.; Zhou, F.; Ke, H.; Lu, W.; Zhang, S.; Zhang, Y.; Yang, S.; et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p. Biomed. Pharmacother. 2017, 97, 1182–1188. [CrossRef] [PubMed]
17. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447, 1130–1134. [CrossRef] [PubMed]
18. Tarasov, V.; Jung, P.; Verdoodt, B.; Lodygin, D.; Epanchintsev, A.; Menssen, A.; Meister, G.; Hermeking, H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007, 6, 1586–1593. [CrossRef] [PubMed]
19. Chang, T.C.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J.; et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26, 745–752. [CrossRef] [PubMed]
20. Raver-Shapira, N.; Marciano, E.; Meiri, E.; Spector, Y.; Rosenfeld, N.; Moskovits, N.; Bentwich, Z.; Oren, M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26, 731–743. [CrossRef] [PubMed]
21. Lin, X.; Lin, B.W.; Chen, X.L.; Zhang, B.L.; Xiao, X.J.; Shi, J.S.; Lin, J.D.; Chen, X. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem. Biophys. Res. Commun. 2017, 493, 1464–1470. [CrossRef] [PubMed]
22. Han, K.; Wei, M.; Zhang, J.J.; Zhou, Y.; Wang, Y.L.; Su, Y.; Lin, S.C.; Gan, Z.H.; Sun, Y.N.; Min, D.L. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016, 9, 3085–3094. [CrossRef] [PubMed]
23. Wang, L.; Wang, J. Luteolin induced apoptosis in breast cancer cell by decreasing the expression of microRNA-21. Chongqing Med. 2013, 42, 1374–1376.
24. Wu, H.; Huang, M.; Liu, Y.; Shu, Y.; Liu, P. Luteolin induces apoptosis by up-regulating miR-34a in human gastric cancer cells. Technol. Cancer Res. Treat. 2015, 14, 747–755. [CrossRef] [PubMed]
25. Shi, H.; Zhou, S.; Liu, J.; Zhu, J.; Xue, J.; Gu, L.; Chen, Y. MiR-34a inhibits the in vitro cell proliferation and migration in human esophageal cancer. Pathol. Res. Pract. 2016, 212, 444–449. [CrossRef] [PubMed]
26. Wang, J.X.; Zhang, Q.J.; Pei, S.G.; Yang, B.L. Effect and mechanism of miR-34a on proliferation, apoptosis and invasion of laryngeal carcinoma cells. Asian Pac. J. Trop. Med. 2016, 9, 494–498. [CrossRef] [PubMed]
27. Gao, J.; Li, N.; Dong, Y.; Li, S.; Xu, L.; Li, X.; Li, Y.; Li, Z.; Ng, S.S.; Sung, J.J.; et al. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene 2015, 34, 4142–4152. [CrossRef] [PubMed]
28. Lu, H.; Hao, L.; Li, S.; Lin, S.; Lv, L.; Chen, Y.; Cui, H.; Zi, T.; Chu, X.; Na, L.; et al. Elevated circulating stearic acid leads to a major lipotoxic effect on mouse pancreatic beta cells in hyperlipidaemia via a miR-34a-5p-mediated PERK/p53-dependent pathway. Diabetologia 2016, 59, 1247–1257. [CrossRef] [PubMed]
29. Ding, N.; Wu, H.; Tao, T.; Peng, E. NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2. Onco Targets Ther. 2017, 10, 4905–4915. [CrossRef] [PubMed]
30. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. Cell 2009, 137, 413–431. [CrossRef] [PubMed]
31. Hsu, Y.F.; Lee, T.S.; Lin, S.Y.; Hsu, S.P.; Juan, S.H.; Hsu, Y.H.; Zhong, W.B.; Lee, W.S. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells. Mol. Carcinog. 2007, 46, 275–283. [CrossRef] [PubMed]
32. Wang, H.; Yan, C. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 2011, 13, 611–619. [CrossRef] [PubMed]
33. Chakraborty, S.; Mazumdar, M.; Mukherjee, S.; Bhattacharjee, P.; Adhikary, A.; Manna, A.; Chakraborty, S.; Khan, P.; Sen, A.; Das, T. Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett. 2014, 588, 549–559. [CrossRef] [PubMed]
34. Hu, Z.; Fan, H.; Lv, G.; Zhou, Q.; Yang, B.; Zheng, J.; Cao, W. 5-Aminolevulinic acid-mediated sonodynamic therapy induces anti-tumor effects in malignant melanoma via p53-miR-34a-Sirt1 axis. J. Dermatol. Sci. 2015, 79, 155–162. [CrossRef] [PubMed]
35. Mandke, P.; Wyatt, N.; Fraser, J.; Bates, B.; Berberich, S.J.; Markey, M.P. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS ONE 2012, 7, e42034. [CrossRef] [PubMed]
36. Ou, X.; Lu, Y.; Liao, L.; Li, D.; Liu, L.; Liu, H.; Xu, H. Nitidine chloride induces apoptosis in human hepatocellular carcinoma cells through a pathway involving p53, p21, Bax and Bcl-2. Oncol. Rep. 2015, 33, 1264–1274. [CrossRef] [PubMed]
37. Brentnall, M.; Rodriguez-Menocal, L.; de Guevara, R.L.; Cepero, E.; Boise, L.H. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013, 14, 32. [CrossRef] [PubMed]
38. Zhu, L.; Han, M.B.; Gao, Y.; Wang, H.; Dai, L.; Wen, Y.; Na, L.X. Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. Mol. Med. Rep. 2015, 12, 1151–1156. [CrossRef] [PubMed]
39. Cai, X.; Ye, T.; Liu, C.; Lu, W.; Lu, M.; Zhang, J.; Wang, M.; Cao, P. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol. In Vitro 2011, 25, 1385–1391. [CrossRef] [PubMed]
40. Jiang, Z.Q.; Ma, Y.X.; Li, M.H.; Zhan, X.Q.; Zhang, X.; Wang, M.Y. 5-Hydroxymethylfurfural protects against ER stress-induced apoptosis in GalN/TNF-α-injured L02 hepatocytes through regulating the PERK-eIF2α signaling pathway. Chin. J. Nat. Med. 2015, 13, 896–905. [CrossRef]